AMGN vs. ONC: Amgen vs. BeOne Medicines Stock Comparison
How do Amgen (AMGN) and BeOne Medicines (ONC) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Amgen (AMGN) and BeOne Medicines (ONC) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Amgen (AMGN) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | AMGN | ONC |
|---|---|---|
| Name | Amgen Inc. Common Stock | BeOne Medicines Ltd. American Depositary Shares |
| Country/Region | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 249.05 billion USD | 46.49 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 17, 1983 | February 3, 2016 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AMGN | ONC |
|---|---|---|
| Total Return (1Y) | 48.82% | 30.59% |
| Total Return (3Y, Annualized) | 24.31% | 30.15% |
| Total Return (5Y, Annualized) | 20.67% | 2.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AMGN | ONC |
|---|---|---|
| Volatility (1Y, Annualized) | 29.12% | 35.90% |
| Beta (5Y) | 0.43 | 0.59 |
| Max Drawdown (5Y) | -24.86% | -68.89% |
| Avg. Volume (3M) | 2.76M | 405.29K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AMGN | ONC |
|---|---|---|
| Sharpe Ratio (1Y) | 1.53 | 0.73 |
| Sortino Ratio (1Y) | 2.36 | 1.15 |
Profitability
ROE (TTM)
Both Amgen (AMGN) at 78.35% and BeOne Medicines (ONC) at 18.40% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
78.35%
- Max
- 109.18%
- AMGN
- 78.35%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Amgen (AMGN) at 24.14% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.14%
- AMGN
- 24.14%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Amgen (AMGN) at 35.79% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.79%
- Max
- 83.12%
- AMGN
- 35.79%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AMGN | ONC |
|---|---|---|
| ROE (TTM) | 78.35% | 18.40% |
| ROA (TTM) | 8.91% | 8.42% |
| Net Margin (TTM) | 24.14% | 13.86% |
| Operating Margin (TTM) | 35.79% | 22.15% |
| Gross Margin (TTM) | 72.47% | 89.39% |
Growth
Revenue Growth
Both Amgen (AMGN) at 9.95% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Amgen (AMGN) reports EPS growth of 88.23%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.
Growth Metrics
| Metric | AMGN | ONC |
|---|---|---|
| Revenue Growth (YoY) | 9.95% | 40.23% |
| Revenue Growth (3Y CAGR) | 11.77% | 55.69% |
| EPS Growth (YoY) | 88.23% | -- |
| EPS Growth (3Y CAGR) | 5.52% | -- |
Financial Strength
Current Ratio (MRQ)
BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Amgen (AMGN) at 1.48 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AMGN.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AMGN
- 1.48
- Min
- 0.10
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
BeOne Medicines (ONC) at 0.35 is near its industry mid-range for debt-to-equity ratio, while Amgen (AMGN) at 3.76 sits above its benchmark range, pointing to a heavier debt load relative to equity.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.76
- AMGN
- 3.76
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AMGN | ONC |
|---|---|---|
| Current Ratio (MRQ) | 1.48 | 3.55 |
| Debt / Equity (MRQ) | 3.76 | 0.35 |
| Net Debt / EBITDA | 2.31 | -2.80 |
Dividends
Dividend Yield (TTM)
BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.16%
- AMGN
- 2.16%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
BeOne Medicines (ONC) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
57.62%
- AMGN
- 57.62%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AMGN | ONC |
|---|---|---|
| Dividend Yield (TTM) | 2.16% | 0.00% |
| Dividend Payout Ratio (TTM) | 57.62% | 0.00% |
Valuation
P/E Ratio (TTM)
Amgen (AMGN) at 26.69 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.69
- Max
- 85.34
- Q3
- 43.46
- AMGN
- 26.69
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Amgen (AMGN) at 6.40 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.40
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- AMGN
- 6.40
- Q1
- 3.01
- Min
- 0.01
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: BeOne Medicines (ONC) at 7.98 sits in the upper P/B ratio quartile, and Amgen (AMGN) at 17.35 prices even higher, above its industry range.
AMGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.35
- AMGN
- 17.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AMGN | ONC |
|---|---|---|
| P/E Ratio (TTM) | 26.69 | 52.17 |
| P/S Ratio (TTM) | 6.40 | 7.04 |
| P/B Ratio (MRQ) | 17.35 | 7.98 |
| Free Cash Flow Yield (TTM) | 2.96% | 2.21% |